Status: Recruiting
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
Participants needed: 796
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: DualityBio Inc.Updated: Jan 28, 2026Locations: 102
Eligibility criteria
Has a pathologically documented HER2-positive or HER2-expressing (except for coh... [+7]
History of symptomatic CHF (New York Heart Association [NYHA] classes II-IV) or... [+9]